USE OF ULINASTATIN FOR TREATING SEVERE ACUTE RESPIRATORY SYNDROME AND PHARMACEUTICAL COMPOSITION OF ULINASTATIN

/Home/Lyophilization and Protein Formulation Patents/Patent Articles - Lyophilization/European Patents - Lyophilization

Patent Number: WO2004103399
Publication date: 2004-12-02
Inventor(s): FU HELIANG [CN]; MIAO PIQU [CN]; WANG XIAOYAN [CN]; XIE YONGLI [CN]
Applicant(s): GUANGDONG TECHPOOL BIOCHEM PHA [CN];; FU HELIANG [CN];; MIAO PIQU [CN];; WANG XIAOYAN [CN];; XIE YONGLI [CN]
Requested Patent: WO2004103399
Application Number: WO2004CN00533 20040525
Priority Number(s): CN20030125188 20030526
IPC Classification: A61K38/57; A61K9/08; A61K9/19; A61P31/14; A61P11/00
EC Classification:
Equivalents: CN1160123C, CN1449823
Cited Documents: EP0327999; JP2000336041
Abstract
Use of Ulinastatin for treating and/or preventing Severe Acute Respiratory Sindrome (SARS) and pharmaceutical composition of Ulinastatin. Ulinastatin are effective for treating and/or preventing SARS, particularly for treating and/or preventing Acute Lung Injury (ALI) or Acute Respiratory Distress Syndrome (ARDS). The agent is usually in the form of freeze-dried power for injection and/or injection.

Data supplied from the esp@cenet database - l2